2019
DOI: 10.21470/1678-9741-2019-0043
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Transcutaneous energy transfer system and better biocompatibility could probably be the most important factors in the near future for VADs. This kind of advances will be capable of yielding better quality of life with reduced risk of complications for this population of patients.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 9 publications
0
3
0
Order By: Relevance
“…Despite the positive survival outcomes, we have several adverse events in VAD therapy as well. Bleeding and thromboembolic events, device‐related infections, device malfunction, and neurological complications 43 are among the most relevant serious adverse events. Aortic insufficiency and right ventricular failure are other complications of chronic support with continuous‐flow pumps 40 .…”
Section: The Role Of Cardiac Xtx In the Vad Eramentioning
confidence: 99%
“…Despite the positive survival outcomes, we have several adverse events in VAD therapy as well. Bleeding and thromboembolic events, device‐related infections, device malfunction, and neurological complications 43 are among the most relevant serious adverse events. Aortic insufficiency and right ventricular failure are other complications of chronic support with continuous‐flow pumps 40 .…”
Section: The Role Of Cardiac Xtx In the Vad Eramentioning
confidence: 99%
“…This device was approved in 2002 by the Food and Drug Administration (FDA). However, it did not become the favored choice of patients and cardiologists because of its giant pump size, adverse outcomes and limited durability (with pump failure overtime after 18-30 months of usage) [7].…”
Section: Reviewmentioning
confidence: 99%
“…As previously stated, OHT is contraindicated for patients with fixed pulmonary hypertension (PH) or elevated pulmonary vascular resistance (PVR) and other options for this select group of patients have emerged with time. One of them was the result of researches by Michael Ellis DeBakey and colleagues that culminated with the first successful left ventricular assistance device (LVAD) implantation in 1966 [ 3 ] . These devices benefited a relevant pool of patients eligible for a bridge to transplantation, by providing a progressive reduction of PVR through the reverse remodeling of pulmonary artery branches, making these patients viable candidates for OHT.…”
Section: Introductionmentioning
confidence: 99%